foto
LATEST NEWS

OctoPlus enters into drug development and manufacturing contract with Ferring Pharmaceuticals A/S



WEBCAST HALF-YEAR RESULTS 2011

Click here to access the webcast of 29 July 2011



OCTOPLUS ANNUAL REPORT 2010
OCTO SHARE PRICE
HOME dashNL dash CONTACT
februari 4, 2012

 

OVERVIEW

OctoPlus uses its proprietary drug delivery technologies to develop controlled release products for clients

We engage in new product opportunities with partners that provide an active ingredient that may be improved by combining it with our drug delivery technologies.

We are flexible in forming partnerships to develop improved therapeutic formulations. We are currently performing feasibility studies for a number of clients in which the combination of our technology with the client's therapeutic ingredient is evaluated.

A number of products based on our controlled release technology is now available for licensing.

If you're interested in more information about our technologies or about licensing opportunities, please contact our business development department.